NGeneBio Finalizes 80% Dilutive Rights Offering Registration Statement – Severe Shareholder Dilution and Financial Risk
This registration statement finalizes the terms of a 22.4 billion KRW rights offering, issuing 7.15 million new shares representing 80.01% of existing shares at a 25% discount.
Proceeds of 17.3 billion KRW will be used for working capital including NGS technology upgrades and pharmaceutical distribution, while 5.1 billion KRW will repay high-interest debt.
As of Q1 2026, the company had accumulated deficit of 75.8 billion KRW, debt ratio of 224%, and current ratio of 48%, indicating extreme financial distress.
The company faces a risk of being designated as a managed stock if additional losses exceed 15 billion KRW in 2026, and a risk of delisting if losses exceed 36.9 billion KRW triggering capital erosion over 50%.
The largest shareholder's stake will drop from 21.95% to 17.07%, and potentially to 12.75% if convertible bonds and stock options are exercised.
New shares are not subject to lock-up; if rights are not fully subscribed, the underwriter may acquire them at a 20% discount, leading to potential short-term selling pressure.
[AI Summary]NGeneBio's rights offering is executed under extreme dilution and financial distress, with most funds allocated to debt repayment and working capital, prioritizing survival over growth. Without a significant turnaround in operating performance and financial health, the risk of managed stock designation and delisting remains very high.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)